How to Write a Business Plan
Turn your Project into an Investment Magnet – £300 (we are in Beta) free E-course
Pharmaceutical and Biotechnology projects need a business plan if they are going to raise finance, and that is just what we are here to help you achieve. We are going to assist you in putting together a business plan that will ensure that your healthcare technology project gets the funding it needs. We will turn your project into an investment magnet. Good business plans raise money and you are going to be very please you took our advice, sign up now for our course.
Over the years IDA consultants have worked with a large number of companies to undertake the planning process and provide the contents they need for their business plan, and 100% of our clients obtained the funding they needed to take them to the next step.
£300 (we are in Beta Free) E-course on How to Write a Business Plan
Our £300 (we are in Beta) Free E-course on how to write a business plan will take you through an 11 step programme and provides an outline of the sections of the business plan, guidance on the kind of information that is needed and useful resource and document templates. Fill in the Form to Join and Turn Your Business into an Investor Magnet.
Sign up for £300 Free (we are in Beta)
We don’t like spam, we will not share your data and we will guard it like you would.
Course Content
- Session 1 – Situation Review; before you can decide where your going, its important to understand where you are now.
- Session 2 – Indication Review; what is your target indication? what other opportunities are there? its all about adding value.
- Session 3 – Intellectual Property; this is where your value lies, its critical to protect and optimize it, its not just about patents.
- Session 4 – Regulatory Strategy; the regulations are the gatekeepers to the market and the correct strategy can be the difference between success and failure. You will be a success.
- Session 5 – Markets; its not market sizes its market dynamics, investors know this, do you?
- Session 6 – Indication Selection; make sure your going for the correct markets to optimize your goals and strategies.
- Session 7 – Development planning; how are you going to develop this product? quickly and cost effectively? its risk management.
- Session 8 – Manufacturing and GMP; knowing how the requirements will impact on your business is critical to cash flow and strategy.
- Session 9 – Regulatory Advice, get your plans rubber stamped, it adds masses of credibility, a real investor magnet.
- Session 10 – Cost and Financial Planning; you know what your going to do, but just how much is it going to cost?
- Session 11 – The Business Plan; bringing it all together to attract the investment.
The Book
This course is extracted from the definitive book on How to Write a Business Plan for Health Technology Companies. We will make this book avaialble to you shortley, its just undergoing its final edit and will soon be printed.
Take advantage of our 100% fundraising record when writing your business plan.
Pingback: Drug Regulatos Publish Draft Reflection Paper on In-vitro Cultured Chondrocyte Containing Products for Cartilage Repair | Drug Development Consultant and Regulatory Consultant
Pingback: Regulators Publish Draft Guidance for industry on Risk Evaluation and Mitigation Strategies (REMS) | Drug Development Consultant and Regulatory Consultant
Pingback: The purpose of this guidance is to assist sponsors in clinical drug development for the treatment of adults with duodenal ulcers caused byHelicobacter pylori (H. pylori) for the reduction of duodenal ulcer recurrence. Specifically, this guidance addresses
Pingback: EU Directive updated, - Advanced Therapy Medical Products | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators EMEA publish Draft Guidance on the Use of Near Infrared Spectroscopy | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators Publish Concept Paper on the Need to Revise Clinical Guidance for Depression | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish a Good Review Practice Guidance for Labeling for Human Prescription Drug and Biological Products | Drug Development Consultant and Regulatory Consultant
Pingback: FDA Publishes Guidance on Circular Information for the Use of Human Blood and Blood Components | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish Draft Guidance on IND's for Minimally Manipulated, Unrelated Allogenic Placental/Umbilical Cord Blood | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish Guidance for Minimally Manipulated, Unrelated Allogenic Placental/Umbilical Cord Blood Intended for Hematopoiteic Reconstitution for Specific Indications | Drug Development Consultant and Regulatory Consultant
Pingback: Medical Device Regulators Publish Guidance on Vigilance Systems Breast Implants | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Re-Publish Guidance on Special Populations Geriatrics | Drug Development Consultant and Regulatory Consultant
Pingback: Liver Toxicity, FDA DILI Regulations Require Interpretation | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulator, EMEA, Publishes ICH Guidance on the use of Oncolytic Viruses | Drug Development Consultant and Regulatory Consultant
Pingback: European Commission Publishes Assessment of the Functioning of the Clinical Trials Directive | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA (CDER), Publishes Guidance on SPL Standard for Content of Labeling Technical Qs & As | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA CDER, Publish Updated Guidance on Investigator Responsibilities for Study Subjects | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish Concept Paper on Revision of Guidelines on Radiopharmaceuticals Based on Monoclonal Antibodies | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish Guidance on Nucleic Acid Tests to Reduce Risk of West Nile Virus from Whole Blood Donors | Drug Development Consultant and Regulatory Consultant
Pingback: MHRA puts new Traditional Herbal Medicines Registration Scheme Page Live | Drug Development Consultant and Regulatory Consultant
Pingback: MHRA Re-Publish Guidance On How they Regulate Traditional Herbal Medicines (THMRS) | Drug Development Consultant and Regulatory Consultant
Pingback: EMEA Publishes Draft Guidance on the Development of Medical Products for Insomnia | Drug Development Consultant and Regulatory Consultant
Pingback: Medical Device Classification not Centrally Stored | Drug Development Consultant and Regulatory Consultant
Pingback: FDA Convenes Meeting Regarding Online Advertising | Drug Development Consultant and Regulatory Consultant
Pingback: EMEA Publishes Comments Received on Development of Guidance for Products for Treating Smoking | Drug Development Consultant and Regulatory Consultant
Pingback: FDA Publishes Draft Guidance on E7 Studies in Support of Special Populations: Geriatrics Q&A | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, CHMP Publish Guidance on Follow-up Patients Adminstered with Gene Therapy Medical Products | Drug Development Consultant and Regulatory Consultant
Pingback: Department Of Health Announce an Innovation Pass Pilot | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish Reflection Paper on the Extrapolation of Results from Clinical Studies Conducted Outside the EU | Drug Development Consultant and Regulatory Consultant
Pingback: Good Publication Practice for Communicating Company Sponsored Medical Research; the GPP2 Guidelines Published | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish Q4B Evaluation and Recomendations for Pharmacopeial Texts for use in ICH regions, Annex 11: Capillary Electrophoresis General Chapter | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish Draft Guidance on Manufactures of Human Cells,Tissues and Cellular and Tissue Based Products | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulator, EMEA, Publishes New Visual Identity, web/email addresses and organisation chart for the European Medicines Agency | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish Q4B Evaluation and Recommendations for Pharmacopeial Texts for use in ICH regions, Annex 12: Analytical Sieving General Chapter | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators Publish, ICH Q4B, Annex 7 Dissolution Test General Chapter Guidance | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publishes Guidance on Pharmaceutical Development Q8(R2) | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, CDER, Publish Draft Guidance on Assay Development for Immunogenicity Testing of Therapeutic Proteins | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish Addendum to ICH S6: preclinical safety evaluation of biotechnology-derived pharmaceuticals S6(R1) | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators Publish, ICH M2, Business Requirements Guidance | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, Publish Questions and Answers on GMP, and Production, Process, Control | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish Concept Paper on the Need for Clinical Guidelines for the Investigation of Medicinal Products for the Treatment of Systemic and Cutaneous Lupus Erythematosus | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish ICH S9 Guidance, Nonclinical Evaluation for Anticancer Pharmaceuticals | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish ICH M2, Common Technical Document, Updated Q&A | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish Concept Paper on the Development of a Guidance on Similar Biological Medicinal Products Containing Monoclonal Antibodies | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA, CDER, Publish Guidance on Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish Guidline on Xenogenic Cell-Based Medicinal Products | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, EMEA, Publish ICH Q4B, Annex 10, Polyacrylamide Gel Electrophoresis General Chapter Guidance | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulator, MHRA, Starts Consultation on Measures to Strengthen the Medicines Supply Chain and Reduce the Risk of Counterfit Medicines | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulator, MHRA, Publishes an Updated Guide for Manufactures on Clinical Investigations to be Carried out in the UK | Drug Development Consultant and Regulatory Consultant
Pingback: Drug Regulators, FDA CDER, Publish Guidance on Q4B Annex5 Disintegration Test General Chapter for ICH regions | Drug Development Consultant and Regulatory Consultant